Home / Market News / $SCNX

$SCNX news and market catalysts

The 6 most recent market catalysts affecting $SCNX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

6 catalysts 1 high impact 5 bullish 1 bearish Biotechnology/Pharmaceuticals
Oct 22, 2026 Corporate Catalyst Bullish Impact 75
Scienture Holdings Issues Shareholder Letter Highlighting Financial and Commercial Progress
Scienture Holdings released a shareholder letter highlighting substantial sequential revenue growth of 256% for the first nine months of the year. This significant financial improv…
Oct 13, 2026 Corporate Catalyst Bullish Impact 75
EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability
Scienture Holdings Inc. (SCNX) announced preliminary third-quarter revenue of $1.22 million, a substantial 256% increase from the previous quarter. This growth is primarily attribu…
Oct 2, 2026 Corporate Catalyst Bullish Impact 65
EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions
Scienture Holdings (SCNX) secured formulary additions for its hypertension drug, Arbli, in three leading pediatric hospitals. This is a positive development as it expands the drug'…
Oct 1, 2026 Corporate Catalyst Bearish Impact 75
Scienture Holdings (SCNX) Stock Drops 19% After Hours: Here's What Happened
Scienture Holdings announced a 1-for-25 reverse stock split, a corporate action typically undertaken by companies whose stock price has fallen significantly. The primary stated rea…
Aug 14, 2026 Corporate Catalyst Bullish Impact 85
Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate
Scienture Holdings (SCNX) reported its Q2 earnings, showing a mixed performance. While the company managed to beat analyst estimates for earnings per share, reporting a loss of $(0…
Aug 12, 2026 Corporate Catalyst Bullish Impact 75
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US
Scienture Holdings (SCNX) has announced the commercial rollout of Rezenopy, its 10mg naloxone nasal spray, which is the highest-dose product of its kind on the market. This is a si…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.